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ABSTRACT 
 
Ikaros - a factor that positively or negatively controls gene transcription - is active in murine adult 
erythroid cells, and involved in fetal to adult globin switching. Mice with Ikaros mutations have defects 
in erythropoiesis and anemia. In this paper, we have studied the role of Ikaros in human erythroid 
development, for the first time. Using a gene–transfer strategy, we expressed Ikaros 6 (Ik6) - a known 
dominant negative protein that interferes with normal Ikaros activity -  in cord blood or apheresis 
CD34+ cells that were induced to differentiate along the erythroid pathway. Lentivirally-induced Ik6 
forced expression resulted in increased cell death, decreased cell proliferation; decreased expression 
of erythroid-specific genes including GATA1, fetal and adult globins. In contrast, we observed the 
maintenance of a residual myeloid population that can be detected in this culture system, with a 
relative increase of myeloid gene expression, including PU1. In secondary cultures, expression of Ik6 
favored reversion of sorted and phenotypically defined erythroid cells into myeloid cells, and prevented 
reversion of myeloid cells into erythroid cells. We conclude that Ikaros is involved in human adult or 
fetal erythroid differentiation, as well as in the commitment between erythroid and myeloid cells. 
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INTRODUCTION 
 
The transcription factor Ikaros (also known as LyF-1) was first described to interact with Cd3δ and TdT 
promoters in murine thymocyte cells 1,2. Its sequence is highly conserved between mice and humans 3-
5
 and its expression is high in the developing and adult hematopoietic systems 1,6. Ikaros proteins are 
characterized by the presence of two Krüppel-like zinc finger domains. The N-terminal domain is 
involved in DNA binding 2,7, while the C-Terminal domain is required for homo- or hetero-dimerization 
with family members and is composed of 2 zinc fingers 8. The Ikaros gene contains 7 translated exons 
and encodes nine isoforms, by means of alternative splicing that alters expression of exons 3-6 2,7. In 
these different proteins, the number of N-Terminal zinc fingers varies from 0 to 4 ; this combination 
determines DNA binding affinity. At least 3 zinc fingers in this domain are necessary to efficiently bind 
to DNA. Ik1, Ik2, Ik3 and IKX are considered as functional isoforms. However, Ik4 can only bind DNA 
on palindromic sequences 7. Ik5, Ik6, Ik7 and Ik8 are considered as dominant-negative (DN) isoforms 
because of their capacity to bind other isoforms, and their inefficiency to bind DNA 8.  
Gene targeting studies evidenced the fundamental role of Ikaros in hematopoiesis, in particular in T 
and B lymphocytes, NK and dendritic cells, and stem cells 9-12. In addition, analysis of Ikaros L/L mice 
(insertion of the β-Gal gene in exon-2 of the Ikaros gene) revealed  that Ikaros is expressed at low 
levels in a majority of Ter-119+ erythroid cells 10. Other studies of Ikaros DN (deletion of exon 7) and 
null (deletion of dimerization domain) mice show that Ikaros is important for erythroid differentiation 13. 
These mice display a decrease of erythroid precursor numbers, and a drop in hematocrit levels 2-3 
weeks after birth. In MEL (murine erythro-leukemia) cells, Ikaros is associated with the chromatin 
remodelling PYR complex which binds to an intergenic domain between the γ-Globin and β-Globin 
genes, and facilitates the switch between these two globins 14. Moreover, Ikaros null mice show a 
delay in murine embryonic to adult β-globin switching, due to the lack of the chromatin remodeling 
PYR complex. Delayed switching between human γ- and β-globins is also observed in mice with a 
human β-Globin minilocus and lacking the Ikaros gene 15. These studies show that Ikaros is necessary 
to the formation of the PYR complex, and to switching of murine and human globins 16,17. The role of 
Ikaros in erythropoiesis is confirmed by another Ikaros mutation : Ikaros plastic mice have a single 
amino acid change in the third zinc finger of the N-Terminal domain (ENU-induced nucleotide 
mutation), and die between E15.5 and E17.5 with severe anemia 18; numbers of erythroid progenitors 
(CFU-E and BFU-E), normoblasts and non nucleated reticulocytes are reduced which is due to a 
failure of normal erythroblast growth and differentiation.  
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The earliest committed erythroid progenitor is the erythroid burst-forming unit (BFU-E) which then 
differentiates in erythroid colony-forming units (CFU-E). The more immature morphologically 
identifiable cells are proerythroblasts. Hemoglobinization begins at the basophilic stage, and increases 
in polychromatophilic erythroblasts 19. Orthochromatophilic erythroblasts undergo terminal maturation, 
including extrusion of the nucleus to produce enucleated mature erythrocytes. The human β-globin 
locus contains different genes which are successively expressed during ontogeny 16,20,21. Gamma-
globin genes are first expressed in fetal liver and cord blood (CB) erythropoiesis  19,22. Shortly after 
birth, a switch between fetal and adult globins allows the expression of δ- and β-globin genes, and the 
decrease of γ-globin gene expression 21,23,24. Adult erythropoiesis recapitulates fetal-to-adult 
hemoglobin switching, in the so-called “compressed switch” 25-27. Fetal-to-adult switch needs 
interaction of transcription factors and chromatin remodeling proteins with the Locus Control Region 
(LCR) 16,17,21,28. Analyses of transcription factors revealed the importance of erythropoiesis regulation 
at the transcriptional level GATA1 is crucial for differentiation, expression of erythroid genes (such as 
β-globin, FOG1, EKLF, NFE2), and for survival of erythroid cells 29. GATA-1 functions are in part 
controlled by interaction with FOG1, which is itself involved in terminal erythroid maturation 30. EKLF 
allows expression of β-Globin and the erythropoietin receptor, and is essential for switching process 
between γ- and β-globin in adult erythroid cells 31,32. NFE2 is also involved in α- and β-globin 
expression 33. In contrast, the Ets factor PU1, which promotes differentiation of lymphoid and myeloid 
lineages, inhibits erythroid differentiation through its antagonism with GATA1, whereas it is necessary 
for proliferation of early erythroid progenitors 34.  
In this work, we studied the role of Ikaros in human erythropoiesis from CB, and its role in globin 
switch in adult cells. Using a similar strategy as in a previous study 35, we inhibited Ikaros function by 
over-expression of the DN Ik6 isoform throughout in vitro erythroid differentiation from CB or apheresis 
CD34+ progenitor cells.  
MATERIALS AND METHODS 
  
Primary cells and cell lines. 
Cord blood (CB) or apheresis (adult mobilized Peripheral Blood : mPB) samples were obtained after 
informed consent from pregnant mothers or cancer patients respectively. CD34+ cells were enriched 
from CB or mPB mononuclear cells, using immuno-selection with the MACS technology according to 
the manufacter’s recommendations (Miltenyi Biotec, Bergisch-Gladbach, Germany).  
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The MS5 murine stroma cell line was maintained in DMEM (Cambrex) supplemented with 10% Fetal 
Calf Serum (FCS) (Invitrogen, Paisley, UK), 100 U/mL penicillin, and 100 µg/mL streptomycin 
(Invitrogen).  
 
Lentiviral vectors 
The Ik6 cDNA was obtained by PCR with specific primers as previously described 35. The Flag 
sequence was inserted in 5’ of Ik6 cDNA, upstream of the initiation codon. In a first step, mutation of 
ATG for ATC, inserting a ClaI site, was introduced by PCR with primers Ik ClaI start and Ik XhoI stop 
(supplementary Table 1s). The resulting PCR product was subsequently cloned into the pCRII vector 
and sequenced. Flag Bam/Cla Oligos were annealed, introduced in opened BamHI/ClaI Ik6 pCRII 
vector, cloned and sequenced. In a second step, the Flag-Ik6 sequence was cloned into TRIP ∆U3 
EF1α EGFP (a gift from P. Charneau), called EF1 GFP in place of EGFP, using the BamHI and XhoI 
sites 36. This vector was called EF1 IK6 (supplementary figure 1s). Production of lentiviral vectors and 
assays for the detection of replication competent lentiviruses were previously described 37. 
 
Erythropoietic cell cultures and lentiviral transductions  
CD34+ cells from CB or mPB were cultured as previously described 22. Briefly, cells were cultured in 
IMDM supplemented with 20% BIT, 900 ng/mL ferrous sufate, 90 ng/mL ferric nitrate (basal medium). 
In the first step (days 0-10), 104/mL CD34+ cells were cultured in the presence of 10-6M 
hydrocortisone, 100 ng/mL stem cell factor (SCF), 5 ng/mL IL3 and 3 IU/mL erythropoietin. On day 3, 
these cells were transduced with 2500 ng of p24 antigen of lentivirus per 106 cells/mL of culture 
medium, in the presence of protamine sulfate (8µg/mL). After 24h, the lentiviral medium was removed, 
and cells were replated in culture medium at 200,000 cells per 4 mL. In the second step (days 10-13), 
cells were diluted at 5x104 or 105 cells/mL (for CB or mPB respectively), and co-cultured on an 
adherent MS5 stromal layer, in basal medium supplemented with erythropoietin. In the third step (days 
13-20), cells were cultured on MS5 cells, in basal medium without cytokine.  
In an alternative experiment, on day 10, cells were sorted on a FACSAria Flow cytometer in two 
populations either CD13+/GPA- cells or CD13-/GPA+ cells. One half of sorted cells were replated in 
erythroid conditions as previously described. Seven days later, cells were analyzed using flow 
cytometry and quantitative PCR. The second half of sorted cells were plated in “myeloid” medium 
containing IMDM, 20% BIT, IL3 (10ng/ml), IL6 (10ng/ml), G-CSF (10ng/ml), GM-CSF (10ng/ml) and 
SCF (100ng/ml). Seven days later, cells were analyzed using flow cytometry and quantitative PCR.   
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Flow cytometric analyses  
The following mAbs and their isotypic controls were purchased from Beckman-Coulter (Marseille, 
France): FITC and PE-conjugated CD36, PE and PC5-GPA (Glycophorin-A), PE and PC7-CD13 (N-
Aminopeptidase), PE-CD33, PE-CD111 (Nectin 1), PE-CD117 (c-Kit), PE and PC5-CD45, PC5-CD71 
(Transferrin receptor), PC5-CD34.  
After staining, cells were fixed with paraformaldehyde 2% and analyzed with a FACS LSRII flow 
cytometer (Becton Dickinson: BD immuocytometry systems, BDIS, San Jose, CA) equipped with the 
DIVA analysis software.  
Cell death was measured using an Annexin V-Cy5 assay. 
 
Cytospin and immunofluorescence 
The cells were cytospun on glass slides (approximately 100,000 cells per slide) at 800 rpm for 5 min in 
PBS 20% FCS. Analyses of cell morphology and transduction efficiency were performed with either 
May-Grünwald Giemsa or immunofluorescence staining, respectively. We stained cells with a mouse 
anti-flag antibody (2µg/ml) (Sigma), and an alexa-Fluor 488 conjugated anti mouse antibody (2µg/ml) 
(Invitrogen) as secondary antibody. 
 
RNA and DNA  isolation, RT-PCR and Quantitative-PCR 
Total RNA and DNA were extracted from cells with a Nucleospin RNA II kit (Macherey Nagel Hoerdt, 
France). cDNA synthesis was performed as previously described 38. To reveal all Ikaros isoforms, 
classical PCR was done with primers matching sequences on exons 2 and 7 (shown in table1s, 
“Ikaros isoforms”) ; PCR products were loaded on agarose gel stained with Ethidium Bromide.  
Quantitative PCR was performed to evaluate the total amount of endogenous Ikaros mRNA, using 
SYBR Green PCR Master Mix and an ABI7700 system (Applied Biosystem), or using Faststar DNA 
master SYBR Green and a Light Cycler apparatus (Roche). The primers (Table 1s, “Ikaros total”) that 
match in exon 7 were used. Flag Ikaros transgene expression was quantified with Flag Ikaros primers 
(supplementary table 1s “Flag Ikaros”). The plasmid standards for Globin β, Globin γ, Globin α, EKLF, 
NFE2, FOG1 and EPOR were obtained by cloning specific amplicons of each gene with respective 
primers (Table 1s) in pCRII vector using TA-Cloning kit, and sequencing. The plasmid standard for the 
other genes was an image clone (Invitrogen). Gene expression was normalized using the endogenous 
GAPDH gene expression as an internal standard.  
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The expression of 184 apoptotic, transcription factor and cell cycle genes was tested from 2µg of 
cDNA using Sybr Green reagent on an ABI7700 system. Relative gene expression was normalized, 
using four relative endogenous gene expression (GAPDH, HRP1, Ubiquitin, β-Actin) 39.  
 
Immuno-precipitation 
The supernatant of 106 cell NP40 lysis was incubated with anti Tag protein G Sepharose for 3 hours at 
4°C.  Specific anti-Tag proteins were loaded on an acrylamide gel. Western blot was revealed with an 
anti Ikaros antibody (Santa Cruz Tebu France). 
RESULTS 
  
Expression of endogenous Ikaros during erythroid differentiation of CD34+ cells from human CB and 
from human mPB. 
Purified CD34+ cells from human CB and adult mPB were cultured in erythroid conditions, as 
previously described 22. The three culture steps produced similar results in our hands : at the end of 
the first step (day 10), the cell population was composed of 53% proerythroblasts (Pro EB) and 36% 
basophilic erythroblasts (Baso EB). At the end of the second step (day 13), cultured cells comprised 
50% polychromatophilic erythroblasts (Poly EB) and 40% orthochromatophilic erythroblasts (Ortho 
EB). During the third step (13-20 days), 10% Poly EB and 84% Ortho EB, and 100% Ortho EB were 
detected at day 17 (intermediate day) and at day 20 respectively (figure 1A). On days 10, 13, 17 and 
20, total RNA was extracted from normal cultured cells and reverse transcribed into cDNA. Figure 1B 
shows expression of different active endogenous Ikaros isoforms (Ikaros 1 (IK1), Ikaros 2/3 (IK2/3) 
and Ikaros 4 (IK4)) - as well as the absence of endogenous Ik6 - at all stages of CB CD34+ cell 
cultures. The pattern was identical for adult erythroid cultured cells (data not shown). An estimation of 
the total quantity of the mRNAs that encode the different Ikaros isoforms (relative to GAPDH) by 
quantitative PCR did not show significant variations between days 10 and 20 of the cultures (figure 
1C).  
  
Expression of transgenic dominant negative Ikaros 6 isoform during induced erythroid differentiation of 
transduced cells. 
As previously mentioned, we did not detect endogenous Ik6 mRNA in CB or mPB differentiating cells 
(Figure 1B). On day 3 of cultures, fetal and adult cells were transduced with the EF1-GFP or EF1-IK6 
vectors. The percentage of transduction was analyzed using immunofluorescence : 30% of CB 
cultured cells expressed Ik6 on day 10. The relative expression of transgenic Ik6 compared with 
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GAPDH was analyzed by quantitative RT-PCR, on days 10, 13, 17 and 20 : although it decreased 
during CB cell differentiation, transgene expression remained 16 to 59 fold higher than endogenous 
Ikaros expression (Supplementary Figure 2s). Similar results were obtained with transduced adult 
mPB cells (data not shown). 
To confirm interactions between endogenous Ikaros and Ik6, EF1 IK6 transduced CB cells or control 
cells were lyzed on day 7. After immunoprecipitation with an anti-flag antibody, western blots revealed 
with anti-Ikaros showed two bands which correspond to Ik1 and Ik6 (figure 2). These results show that 
transgenic Ik6 was complexed with endogenous Ikaros. 
 
Decrease in cell number and increase in death induced by Ik6 expression . 
To determine the effects of Ik6 expression, untransduced (CTRL) and transduced (EF1 GFP or EF1 
IK6) cells were harvested and counted by trypan blue exclusion on days 10, 13, 17 and 20. In CB cell 
differentiation, numbers were equivalent between CTRL, EF1 GFP and EF1 IK6 cells on days 10 and 
13. However, following erythropoietin-starvation (days 17 and 20), CTRL and EF1 GFP cell numbers 
increased, while EF1 IK6 cells did not. Ik6 cell numbers were significantly lower than for CTRL and 
EF1 GFP (figure 3A). In parallel, the percentage of dead cells measured with an Annexin-V assay 
started to increase at day 13 when CB cells were transduced with EF1 IK6; a modest increase in 
CTRL and EF1 GFP dead cells was observed on day 20, but remained lower than for EF1 IK6 (figure 
3B). In conclusion the significant  decrease of cell numbers in Ik6 transduced cells probably results 
both of an increased cell death rate, and a reduced proliferation.   
 
Ik6 over-expression disturbs erythroid differentiation without impairing the myeloid potential . 
To further determine whether Ik6 expression modified erythroid differentiation, cell surface markers 
including CD36, CD71, GPA and CD111 (“erythroid” markers), CD117 (c-kit) and CD34 (“progenitor” 
markers), CD45 (human hematopoietic marker lost during erythroid differentiation) and CD33 and 
CD13 (“myeloid” markers) were analyzed (figure 4 and supplementary table 2s). No difference 
between control and transduced cells was observed until  day 17 of culture. At days 17 and 20, the 
percentages of erythroid marker positive cells remained equivalent between CTRL, EF1 GFP and EF1 
IK6 cells (figure 4A). However, corresponding EF1 IK6 cell numbers decreased significantly, except for 
CD111 (figure 4B). Percentages of CD117, CD45 and myeloid marker expression increased 
significantly in EF1 IK6 transduced cells (figure 4C), although corresponding cell numbers remained 
unchanged between CTRL, EF1 GFP and EF1 IK6 (figure 4D). Thus, forced expression of Ik6 in CB 
cells resulted in a relative enrichment of the myeloid population at the expense of the erythroid 
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population : the CD13-positive population increased, most of these cells also expressing CD33, 
CD117 and CD45 (Figure 4E) ; however, forced expression of Ik6 did not induce the appearance of 
"biphenotypic” cells co-expressing GPA and CD13. 
 
 
Ik6 over-expression inhibits erythroid gene expression and promotes myeloid gene expression. 
To test effects of Ik6 on expression of selected erythroid (GATA1, EKLF, EPOR, NFE2, FOG1 and α-
Globin) and myeloid (CD13, M-CSFR and PU1) genes, total RNA from cultured cells was extracted at 
days 10, 13, 17 and 20. RT-PCR was performed and gene expression was analyzed using 
quantitative PCR. On days 10 and 13, expression of erythroid genes was unchanged between 
untransduced and transduced cells (data not shown). However, on day 17, following EPO-starvation, 
expression of GATA1, EKLF and EPOR in EF1 IK6 CB cells decreased significantly when compared 
with CTRL (=1) or EF1 GFP cells (figure 5A). At this step, expression of NFE2, FOG1 and α-Globin 
was also decreased in EF1 IK6 CB cells. On day 20, the decrease of these six erythroid genes was 
even more drastic, and was significant for GATA1, EKLF, EPOR, NFE2 and α-Globin (figure 5A).  
By contrast, at days 13, 17 and 20 of CB cell differentiation, expression of several myeloid genes  
progressively increased (figure 5B). Increase in CD13 detection using flow cytometry on EF1 IK6 
transduced cells was confirmed by quantitative RT-PCR throughout differentiation. In parallel, 
expression of M-CSFR in EF1 IK6 cells remained drastically higher than for CTRL and EF1 GFP cells. 
Throughout erythroid differentiation of EF1 IK6 cells, PU1 level of expression was significantly higher 
than that observed in CTRL and EF1 GFP cells. The increase of myeloid gene expression was 
detected before the decrease of erythroid gene expression.  
This was further confirmed by analysis of 90 apoptotic and 94 various gene (transcription factor, cell 
cycle and apoptotic genes) expression using multiplex PCR. In supplementary figure 3sA, 54 apoptotic 
genes appeared to be reproducibly modulated in three independent experiments, on day 17. Among 
up-regulated genes, there were a majority of “myeloid” genes such as cytokine activator caspase 
genes (caspases 1, 4 and 5) .  
Supplementary figure 3sB shows the modification of 50 genes (a selection of our initial set of 94) on 
day 20 of CB cell differentiation. Expression of endogenous Ikaros was not modified in EF1 IK6 cells, 
meaning that transgenic Ik6 did not influence endogenous Ikaros expression. However, Ik6 expression 
induced an increase of genes which are involved in myelopoiesis (PU1, c-jun), or early and late 
erythropoiesis (GATA2, Ets-1), and a decrease of important “late” erythroid genes such as GATA1.  
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Taken together these results suggest that the expression of genes involved in erythroid differentiation 
was decreased in the Ik6 transduced population, while that of genes involved in myeloid differentiation 
was increased. 
 
 
Ik6 over-expression prevents human globin switch 
Gamma- and β-Globin expression in CB EF1 IK6 cells was drastically reduced at day 17, and 
significantly reduced at day 20 (figure 6A). However, the relative expression of the 2 globins in CTRL, 
EF1 GFP and EF1 IK6 cell populations was unchanged throughout CB erythroid differentiation (figure 
6B). Similarly, expression of γ- and β-Globin was dramatically reduced in adult EF1 IK6 cells, at day 
17. During mPB cell erythroid differentiation “compressed switch” occurred : the proportion of γ-Globin 
decreased (59% to 21%) in favor of β-Globin (41% to 79%) expression in CTRL and EF1 GFP cells. 
However, when adult cells expressed Ik6, the proportion of γ-Globin cells (82% to 60%) remained 
higher than β-Globin cells (18% to 40%) on day 10, 13 and 17 (figure 6C), thus suggesting that Ik6 
expression prevented “compressed switch” between γ-Globin and β-Globin in adult cells. 
 
Ik6 over-expression inhibits erythropoiesis and favors myelopoiesis 
To test whether Ikaros is involved in erythoid or myeloid commitment, we sorted two cell populations 
after transduction with EF1 GFP or EF1 IK6, and after 10 days of culture in erythroid conditions : 
CD13+ /GPA- (“myeloid”) cells and CD13- /GPA + (“erythroid”) cells. The two sorted cell populations 
were cultured either in myeloid conditions or in erythroid conditions during 7 days, as shown in figure 
7A. On day 17, sub-cultured cells were analyzed for expression of GPA, CD33, CD13 and CD14 
(figure 7B and C).  
In erythroid conditions, 77 and 80% of CTRL and EF1 GFP “myeloid” cells acquired GPA expression 
respectively, whereas a smaller percentage (43%) of EF1 IK6 “myeloid” cells expressed GPA (figure 
7B). In EF1 IK6 cells, CD13 expression was maintained at 58% instead of 16% or 12% in CTRL or 
EF1 GFP populations. Fifty-one % of EF1 IK6 cells expressed CD33 and 15% expressed CD14, 
whereas fewer CTRL and EF1 GFP cells were CD14 (3 and 1% respectively) and CD33 positive (5 
and 8% respectively). CTRL, EF1 GFP and EF1 IK6 “erythroid” cells preserved GPA expression at 93, 
92 and 97% respectively, in erythroid conditions, as described for CB unsorted cells. Even in erythroid 
conditions, forced Ik6 expression was able to maintain myeloid markers from “myeloid” cells and to 
induce their expression on “erythroid” cells. 
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In myeloid conditions, “myeloid” cells remained CD13-positive, and percentages of GPA, CD14, CD13 
and CD33 cells did not present significant differences between CTRL, EF1 GFP and EF1 IK6 cells 
(data not shown). On the other hand, “erythroid” cells cultured in myeloid conditions during 7 days, lost 
expression of GPA to acquire CD13 and CD33 expression:  43, 51 and 68 % of initially CD13-/GPA+ 
cells were positive for GPA, CD13 and CD33 respectively, in the EF1 GFP protocol, as compared to  
31, 67 and 86% CD33+ in the EF1 Ik6 protocol (figure 7C); rare EF1 GFP and EF1 IK6 cells 
expressed CD14 (1%). Thus, in myeloid conditions, Ik6 expression did not influence myeloid 
differentiation of “myeloid” cells, but amplified myeloid differentiation of “erythroid” cells.  
DISCUSSION 
 
Our results provide one of the first evidences that expression of Ikaros is necessary for normal human 
erythroid differentiation. 
First, we show that several functional isoforms of Ikaros are expressed at several stages of human 
erythroid differentiation, induced in an efficient in vitro culture system. Second, we demonstrate that 
transgenic Ik6 associates with endogenous Ik1 – one the major functional isoforms - in human 
haematopoietic differentiating cells, as shown by immuno-precipitation; our observation adds to 
previous studies demonstrating that interaction between Ik6 and Ik1 prevents activating or repressing 
effects of Ikaros on gene expression 8. Interaction of transgenic Ik6 with endogenous Ikaros proteins is 
associated with a decrease of the erythroid population differentiating from CB CD34+ progenitors; 
oppositely, the residual myeloid population present in control cultures persists at a relatively 
unchanged level in cultures of Ik6 transduced cells.  
 
The observed decrease in differentiating cell numbers is associated with an increase of cell death. 
This observation is consistent with the phenotype of Ikaros plastic mice, that showed dead cells in the 
fetal liver, and a decrease of differentiating and mature erythroid cells 18. These suggest a role for 
Ikaros in promoting human erythroid cell differentiation and survival. 
 
Ikaros appears to be active in the early steps of human erythropoiesis. In fact, transgenic Ik6 over-
expression induced a decrease of hemoglobin, associated to a decrease in GATA1 and its target 
genes: FOG-1, EKLF and EPOR by day 17 of culture. The decrease in formation of GATA1/FOG1 
complexes could in turn induce a decrease of NFE2 and β-Globin expression. GATA1, EKLF and 
NFE2 are also implicated in formation and activation of the β-Globin LCR. Thus, Ikaros could indirectly 
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induce the elaboration of an active structure which is associated with a transactivation of γ- and β-
globin expression. Ikaros also induces expression and switch of globin genes during adult erythroid 
differentiation which recapitulates the switch between γ- and β-globin genes (the so-called 
“compressed switch”). Indeed, in Ik6 mPB cells, no switch occured : γ-globin remained the major 
expressed globin at the expense of β-globin. These observations are at least partly in agreement with 
previous murine studies looking at expression of a partial human β-globin locus (32 kb) in Ikaros null 
mice :  these animals showed no defect in the expression of γ- and β-globin in the absence of Ikaros 
function, a discrepancy with our observations that could be due to interspecies differences or the use 
of a chimeric human / mouse model; however, they presented a blockade of the switch 15. This is 
because Ikaros is normally involved in the PYR complex fixed on the intergenic region. The low EKLF 
expression – a factor necessary to induce the switch 40 – may also contribute to this defect. 
 
Conversely, GATA2 and Ets-1 genes are over expressed in Ik6 cells, while the level of junB gene 
decreases.
 
In erythroid cells, GATA2 and Ets-1 are necessary in progenitors (GATA2 is a proliferative 
gene in early progenitors) but their over-expression interferes with terminal erythroid differentiation 
41,42
. junB is involved in erythroid gene expression and maturation 43. In our culture system, IK6 
erythroid cells expressed c-kit and CD45, that are normally repressed during erythroid differentiation. 
Taken together, the decrease of expression of GATA1 and FOG1, and the remaining expression of c-
kit and GATA2 are compatible with a blockade at the early steps of erythroid differentiation. Thus our 
results suggest that Ikaros is necessary for maturation of human erythroid cells. 
 
These previous observations suggest that Ikaros positively regulates human erythroid differentiation at 
different stages. To address the question of a potential role of Ikaros in erythroid vs myeloid 
commitment, we took advantage of the persistence of a residual population of cells with myeloid 
markers in our culture system. Phenotypically-defined “erythroid” or “myeloid” cells were sorted, and 
sub-cultured either in “erythroid” conditions or in “myeloid” conditions, in an attempt to induce “reverse 
differentiation”. “Erythroid” mock-transduced CB cells cultured in myeloid conditions partially lost 
expression of GPA and acquired myeloid gene expression; this reversion was accentuated by Ik6 
forced expression. On the other hand, “myeloid” mock-transduced CB cells cultured in erythroid 
conditions largely lost CD13 expression and acquired GPA expression. Ikaros 6 expression impairs 
this reversion, and a majority of “myeloid” cells preserved expression of CD13 and CD33. Thus, while 
definitive commitment to the erythroid lineage does not occur in a minority of control cells submitted to 
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culture conditions designed to induce massive erytnroid differentiation, transgenic expression of Ik6 
favors this phenomenon. These effects could be compared with that of the deletion of Pax5 
expression : in these animals, cells were unable to differentiate in B-lymphocytes, but reversed into 
the myeloid or T cell pathways when these cells were cultured in specific conditions 44. This reversion 
was not possible with pro-B cells from normal Pax5+/+ mice which probably had reached a “no return” 
stage with the same phenotype.  
 
It is noteworthy that the sub-population of cells with myeloid makers did not expand in primary cultures 
as a consequence of Ik6 forced expression, although its relative importance increased due to the 
reduced numbers of erythroid cells.  Molecular analyses logically detected a (relative) increase in the 
expression of certain myeloid genes, such as PU1, inflammatory caspases (caspase 1, 4 et 5), M-
CSFR (Macrophage-colony stimulating factor receptor) and c-jun. These observations are in 
agreement with the augmentation of GM-CSFR gene expression in hematopoietic stem cells of 
deficient Ikaros mice 13. PU1-GATA1 antagonism is a well documented mechanism in myeloid vs 
erythroid differentiation 45. However, our preliminary results suggest that Ikaros does not significantly 
affect human myeloid differentiation. 
 
In summary, our studies show for the first time that Ikaros plays a significant role in human 
erythropoiesis. It favors erythoid differentiation. As an hypothetical model it is likely that Ikaros 
functions upstream of GATA1 in this process. Either Ikaros activates directly GATA1, a major gene in 
erythroid differentiation, or indirectly via the E2A/TAL/LMO2/Ldb complex which activates GATA1 with 
GATA2. 
This study adds to the rare publications that describe the role of Ikaros in human hematopoiesis , 
especially in B lymphopoiesis and dendritic cell differentiation 35,46,47. The role of Ikaros in diseases 
has only been described for hematological malignancies, mostly leukemias and lymphomas. The 
search for Ikaros deregulation in other diseases of the stem cell and erythroid compartments may 
provide additional information in the future. 
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FIGURE LEGENDS 
 
Figure 1 : 
Ikaros expression during cytokine induced erythroid differentiation. A. Highly purified CD34+ 
cells from human CB or from human adult mPB samples were maintained in conditions that drive 
differentiation to the erythoid lineage. On day 3, cells were transduced with EF1 GFP or EF1 IK6 
vectors. Cultures were stopped on day 20 for CB samples, and on day 17 for mPB samples. On day 
10, 13, 17 and 20, erythroblast subsets derived from CD34+ CB cells were identified by May-Grünwald 
Giemsa staining. Results are expressed as the mean percentage in 7 independent experiments. B. On 
days 10, 13, 17 and 20, total RNA was extracted from cultured erythroid cells in CB samples and 
expression of endogenous Ikaros isoforms was visualized by ethidium bromide staining of 2% agarose 
gel after RT and 40 cycles of amplification of cDNA with primers designed to match exons 2 and 7 
(Ikaros isoforms in table 1s) in order to amplify all Ikaros isoforms. Arrows indicate the positions of Ik1, 
Ik2/3 and Ik4 expressed isoforms. C. On days 10, 13 and 17, total RNA was also extracted from adult 
cultured erythroid cells. Expression of Ikaros in CB was quantified using quantitative PCR and 
normalized relatively to endogenous GAPDH gene expression. Results are shown with mean +- SEM 
for 4 to 7 independent CB samples. nd : not determined 
Figure 2 : 
Expression of transgenic Ik6 in transduced CB cells. Protein extracts of transduced EF1 GFP or 
EF1 IK6 CB cell were immunoprecipitated at day 7 with an anti-flag epitope antibody, and analyzed by 
western blotting with anti-Ikaros antibody. Arrows indicate the position of Ik1 and Ik6 immuno-detected 
proteins.  
Figure 3 : 
Growth and death of erythroid cells. On day 4, equal numbers of untransduced (CTRL) and 
transduced (EF1 GFP or EF1 IK6) erythroid cells were replated in erythroid conditions.  A. On days 
10, 13 ,17 and 20, living untransduced and transduced erythroid cells derived from CB CD34+ cells 
were counted with trypan blue dye exclusion. The mean cumulative cell numbers of 7 experiments +- 
SEM are shown. *P<0.05 using Wilcoxon test compared to CTRL and EF1 GFP conditions. B. In 
erythroid culture of CB CD34+ cells, percentage of dead cells was determined on days 10, 13, 17 and 
20, using an Annexin V assay. (mean values +- SEM for 7 independent experiments) 
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Figure 4 : 
Effects of Ik6 overexpression on erythroid cell phenotypes. On days 10, 13, 17 and 20, CB 
untransduced and transduced cells were harvested and were analyzed for different cell surface 
markers (erythroid markers : CD36, CD71, GPA and CD111 ; progenitor markers : CD117 (c-kit), 
CD34 ; human hematopoietic maker : CD45 ; myeloid markers : CD33 and CD13) by flow cytometry. 
On day 20, CD36, CD71, GPA and CD111 positive cell percentages (A) and numbers (B) are shown 
(mean +- SEM for 7 independent experiments). On day 20, percentages (C) and numbers (D) of 
CD117, CD34, CD45, CD33 and CD13 positive cells are shown (mean +- SEM for 4 to 7 independent 
experiments). The unchanged results on days 10 and 13 are shown in supplementary data on table 
1s. *P<0.05 using Wilcoxon test compared to CTRL and EF1 GFP conditions ; n.s. not significant. 
Representative dot plots (E) show typical expression of CD13 and GPA, CD13 and CD33, CD13 and 
CD45, CD13 and CD117 on day 20, for transduced and untransduced cell populations.  
Figure 5 : 
Effects of Ik6 over-expression on gene expression during erythroid differentiation. RT-PCR was 
performed using total RNA extracted from cultured cells derived from CB CD34+ cells. Gene 
expression was normalized with GAPDH expression. A. Relative expression of erythroid genes 
(GATA1, EKLF, EPOR, NFE2, FOG1 and α-Globin) on days 17 and 20, comparing untransduced 
(CTRL) erythroid cells (= 1) and transduced cells. Expression of these genes was reduced in EF1 IK6 
erythroid cells. The unchanged results on days 10 and 13 are not shown. B. Relative expression of 
myeloid genes (PU1, M-CSFR, CD13) on days 17 and 20, between untransduced (CTRL) cells (= 1) 
and transduced cells. Expression of these genes was increased in EF1 IK6 erythroid cells. The 
unchanged results on day 10 are not showed, and the results on day 13 were similar with day 17. 
Data are mean values +- SEM for 4 to 7 experiments. *P<0.05 using Wilcoxon test when comparing to 
CTRL and EF1 GFP conditions. n.s. not significant. 
Figure 6 : 
Effects of Ik6 overexpression on γ- and β-Globin genes. On the indicated days, RT-PCR was 
performed using total RNA extracted from cultured erythroid cells derived from CB and mPB  
(Peripheral blood) CD34+ cells. A. Expression of γ-Globin and β-Globin in fetal cDNA erythroid cells 
on days 10, 13, 17 and 20 is normalized to GAPDH gene expression. Data are mean values +- SEM 
for 4 to 7 experiments. *P<0.05 using Wilcoxon test compared to CTRL and EF1 GFP conditions. B. 
Relative expression between γ-Globin and β-Globin in fetal erythroid cells is shown as the mean of 4 
to 7 independent experiments. C. Relative expression between γ-Globin and β-Globin is shown in 
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adult erythroid cells in which “compressed switch” normally occurs, and was delayed in Ik6 transduced 
cells.  
 
Figure 7 : 
Effects of Ik6 over-expression on GPA and CD13 positive sorted cells, that were subsequently 
cultured in erythroid or myeloid conditions. A. CD34+ cells from CB were maintained in erythroid 
condition during 10 days. On day 3, cells were transduced with EF1 GFP and EF1 IK6 vectors. On day 
10, untransduced and transduced cells were stained with CD13-PE and GPA-PC5 antibodies. 
CD13+/GPA- (CD13 positive sorted cells), CD13-/GPA+ (GPA positive sorted cells) were sorted by 
FACS. These two populations were replated in erythroid or myeloid conditions for 7 days, when 
subcultured cells were harvested, living cells were counted by trypan blue exclusion and phenotyped 
for different cell surface markers (erythroid marker : GPA ; myeloid markers : CD14, CD13 and CD33). 
B. Phenotype of erythroid cultured CD13 + sorted cells for CTRL (solid histogram), EF1 GFP (dashed 
line) and EF1 IK6 (large line) conditions. C. Phenotype of myeloid cultured GPA + sorted cells for EF1 
GFP (dashed line) and EF1 IK6 (large line) conditions.  
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